First Personal Financial Services Incyte Corp Transaction History

First Personal Financial Services

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 22, 2020	SELL	$63.18 - $85.97 $694 - $945	-11 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$72.82 - $86.52 $801 - $951	11 New	11 $1,000
Q2 2018 Aug 07, 2018	SELL	$60.85 - $83.98 $24,340 - $33,592	-400 Closed	0 $0
Q1 2018 May 10, 2018	SELL	$83.06 - $100.98 $5,315 - $6,462	-64 Reduced 13.79%	400 $33,000
Q4 2017 Jan 25, 2018	SELL	$93.56 - $116.6 $3,555 - $4,430	-38 Reduced 7.57%	464 $44,000
Q3 2017 Nov 01, 2017	BUY	$109.15 - $138.27 $54,793 - $69,411	502	502 $59,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of First Personal Financial Services, based on Form 13F filings with the SEC.

Stay updated on First Personal Financial Services with notifications on news.